Akebia Therapeutics (NASDAQ:AKBA) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Akebia Therapeutics (AKBA) operate in?

Akebia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Akebia Therapeutics Stock (NASDAQ: AKBA) stock price, news, charts, stock research, profile.

Open	-
Close	-
Volume / Avg.	40.00K / 2.32M
Day Range	- - -
52 Wk Range	0.80 - 2.48
Market Cap	$449.45M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	65
Short Interest	7.72%
Days to Cover	8

Recent News

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disease. Learn about its once-daily oral HIF-PH inhibitor and global approval in 37 countries.

Vandana Singh

Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results.

Avi Kapoor

Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Aug 24

Sep 24

Oct 24

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	40.00K / 2.32M
Day Range	- - -
52 Wk Range	0.80 - 2.48
Market Cap	$449.45M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	65
Short Interest	7.72%
Days to Cover	8

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Akebia Therapeutics (AKBA) stock?

You can purchase shares of Akebia Therapeutics (NASDAQ:AKBA) through any online brokerage.

View our list of the best stock brokerages

Who are Akebia Therapeutics (AKBA) competitors?

Other companies in Akebia Therapeutics’s space includes: KalVista Pharma (NASDAQ:KALV), Celcuity (NASDAQ:CELC), Altimmune (NASDAQ:ALT), Sage Therapeutics (NASDAQ:SAGE) and AnaptysBio (NASDAQ:ANAB).

What is the forecast, or price target, for Akebia Therapeutics (AKBA) stock?

Akebia Therapeutics has a consensus price target of $4.38.

What is the current price for Akebia Therapeutics (AKBA)?

The stock price for Akebia Therapeutics (NASDAQ: AKBA) is $2.06 last updated January 21, 2025 at 8:05 AM EST.

Does Akebia Therapeutics (AKBA) pay a dividend?

There are no upcoming dividends for Akebia Therapeutics.

When is Akebia Therapeutics (NASDAQ:AKBA) reporting earnings?

Akebia Therapeutics’s Q4 earnings are confirmed for Thursday, March 13, 2025.

Is Akebia Therapeutics (AKBA) going to split?

There is no upcoming split for Akebia Therapeutics.

What sector and industry does Akebia Therapeutics (AKBA) operate in?

Akebia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Akebia Therapeutics

Akebia Therapeutics (AKBA) Forecast